Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Certican Filed in Japan for Liver Transplant Rejection: Novartis
April 28, 2017
- Daiichi Sankyo to More than Triple ADC Production Capacities by 2021
April 28, 2017
- Kyowa Kirin Submits Regpara Successor in Japan
April 28, 2017
- Astellas Looking to Xtandi Growth Outside US: President
April 28, 2017
- Astellas Sales Dip 4.4% on Forex Moves, Japan Biz Dented by Price Cuts
April 28, 2017
- Otsuka, Akebia Expand Licensing Pact for Anemia Med Vadadustat
April 27, 2017
- Nippon Kayaku to Codevelop Celltrion’s Rituxan Biosimilar
April 27, 2017
- Janssen Files Japan NDA for Multidrug-Resistant TB Drug
April 26, 2017
- Humira Filed for Pustular Psoriasis in Japan: AbbVie
April 26, 2017
- Mundipharma Japan Chief Voices Eagerness on Rare Cancer Therapies
April 25, 2017
- Kissei Ditches Dry Eye Med KCT-0809
April 25, 2017
- Lumicef PIII Kicks In for Axial Spondyloarthritis: Kyowa Kirin
April 25, 2017
- Drug Costs Can’t Be Curbed with Uniform Pricing of Gx, LLPs: Teva Takeda CEO
April 24, 2017
- With Upsher-Smith Deal Inked, Sawai Looks to Make US Market Its Second Biz Pillar
April 24, 2017
- Janssen’s Sirukumab Exhibits Significant Improvements in Primary Endpoints in Japanese PIII Studies
April 24, 2017
- Benralizumab Demonstrates Favorable Results in Subgroup Analysis of Japanese Bronchial Asthma Patients: AZ
April 24, 2017
- Janssen Files Japan NDA for Psoriasis Med Guselkumab
April 21, 2017
- Lecture Materials Prepared from Information Taken from Medical Charts: Bayer’s Xarelto Issue Whistleblower
April 21, 2017
- Sawai to Buy US Generic Maker Upsher-Smith
April 20, 2017
- Takeda’s “Health Innovation Park” Hoped to Bring Together Various Researchers, Other Companies Also Welcomed
April 20, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…